论文部分内容阅读
泪膜不稳定是干眼症的主要病因,目前人工泪液替代疗法大多仅补充水液层,极少添加脂质成分。改善黏蛋白层的人工泪液是一类治疗干眼症的新型药物,主要包括P2Y2受体激动剂和黏蛋白分泌激动剂,上述两类药物可增加眼表黏蛋白的表达与分泌,改善干眼症的症状与体征,加速眼表损伤修复等。本文就近年来黏蛋白相关的干眼症治疗药物的作用机制,综述临床应用与安全性等研究进展。
Tear film instability is the main cause of dry eye, the current artificial tear replacement therapy mostly only add water layer, add very little lipid composition. Artificial tears to improve mucin layer is a new type of treatment of dry eye drugs, including P2Y2 receptor agonist and mucin secretion agonist, the above two types of drugs can increase the expression and secretion of ocular surface mucin, improve dry eye Symptoms and signs of disease, accelerated repair of ocular surface damage and so on. In this paper, mucin-related treatment of dry eye in recent years, the mechanism of action, review of clinical application and safety research progress.